Biosino and Jianan Clinic Establish Precision Chronic Disease Diagnosis and Treatment Center Focused on Cardio-Cerebrovascular Conditions
According to the "Report on Cardiovascular Diseases in China 2018," the prevalence and mortality rates of cardiovascular and cerebrovascular diseases in China continue to rise, with an estimated 290 million current cases. The burden of cardiovascular disease in China is increasingly heavy, making the prevention and control of chronic cardiovascular and cerebrovascular diseases an urgent priority. VCBeat (WeChat ID: vcbeat) has learned that to further enhance public awareness of chronic diseases, improve national capabilities in chronic disease prevention and control, and provide comprehensive, full-cycle health services, BestNovo (Beijing) Medical Technology Co., Ltd. (hereinafter referred to as "BestNovo") has jointly established a Precision Diagnosis and Treatment Center for Chronic Diseases with Beijing Canaan Clinic (hereinafter referred to as "Canaan Clinic").
Canaan–BestNovo Signing Ceremony
On the afternoon of May 16, 2019, the opening ceremony and unveiling of the Canaan-BestNovo Center for Precision Diagnosis and Treatment of Chronic Diseases were held at Beijing Canaan Clinic. The Canaan-BestNovo Center for Precision Diagnosis and Treatment of Chronic Diseases provides individualized, precision diagnostic and therapeutic services focused on chronic conditions such as cardiovascular and cerebrovascular diseases. It has invited renowned cardiovascular and cerebrovascular specialists from top-tier (Grade A tertiary) hospitals—including Fuwai Hospital, Xuanwu Hospital, Anzhen Hospital, and Peking Union Medical College Hospital—to conduct consultations, thereby establishing specialized, precision care services for chronic cardiovascular and cerebrovascular diseases.
Professor Hui Rutai, Former Vice President of Fuwai Hospital
BestNovo was established in May 2013, at a time when the focus in the genetic testing sector was predominantly on non-invasive prenatal testing (NIPT) and oncology. From the outset, its core team defined a strategic direction focused on precision medicine for cardiovascular and cerebrovascular diseases. Leveraging two decades of accumulated clinical data and scientific research achievements, BestNovo took its first steps in this field and has since gradually expanded into other areas of chronic disease management. Currently, it provides comprehensive and accurate genetic testing and genetic counseling services for various monogenic hereditary cardiovascular diseases, as well as personalized medication guidance for over 100 commonly used drugs, including clopidogrel, warfarin, statins, and folic acid.
Every segment of the genetic testing industry is highly competitive. How can companies advance more rapidly and effectively? BestNovo has chosen the path from genetic testing to integrated precision diagnosis and treatment. The implementation of precision medicine for cardiovascular and cerebrovascular diseases marks the first strategic pillar, embodied by the Canaan-BestNovo Center for Precision Diagnosis and Treatment of Chronic Diseases.
Unveiling Ceremony of the Canaan-BestNovo Precision Diagnosis and Treatment Center for Chronic Diseases
As China’s population ages at an accelerating pace, medical demand in the field of cardiovascular and cerebrovascular diseases is steadily increasing. Although significant progress has been made in the diagnosis and treatment of cardiovascular diseases in China in recent years, traditional diagnostic and therapeutic approaches still have limitations. Precision medicine can substantially reduce healthcare expenditures, alleviate patients’ financial burdens, and improve the efficiency of limited medical resource utilization. How can precision medicine be achieved? By integrating genetic testing with clinical diagnosis and treatment, pursuing both precise diagnosis and precise treatment in tandem.
By effectively integrating more high-quality resources for the diagnosis and treatment of chronic diseases, we aim to maximize service capacity in this field and thereby establish a comprehensive system for the prevention and control of chronic conditions. To this end, Jianan Clinic has entered into an in-depth partnership with BestNovo to jointly explore whole-course management of cardiovascular and cerebrovascular diseases, promote the development of a lifecycle health system, and establish the Jianan-BestNovo Center for Precision Diagnosis and Treatment of Chronic Diseases.
The Center for Precision Diagnosis and Treatment of Chronic Diseases leverages the strengths of Canaan Clinic and BestNovo, integrating medical expert resources and professional capabilities from Peking University Medical Industry Group, BestNovo’s intelligent bioinformatics analysis system and big data resources for precision medicine in cardiovascular and cerebrovascular diseases, as well as a multidisciplinary team comprising cardiovascular and cerebrovascular specialists, medical geneticists, bioinformaticians, and gene testing technology experts. This integration establishes a comprehensive closed-loop service for chronic disease management, encompassing screening, diagnosis, treatment, and ongoing care.
The center boasts abundant expert resources, bringing together authoritative specialists from top-tier tertiary hospitals such as Fuwai Hospital, Beijing Anzhen Hospital, and Peking University Cancer Hospital. It offers specialized outpatient services for hypertension, cardiomyopathy, arrhythmia, pulmonary hypertension, and other conditions, as well as high-level expert consultations, multidisciplinary team (MDT) diagnosis and treatment services.
From personalized screening and diagnosis to disease diagnosis and treatment, and further to full-process, personalized, multidisciplinary collaborative disease management, BestNovo aims to empower patients with chronic cardiovascular and cerebrovascular diseases through its advanced team specializing in molecular diagnostics and therapeutics, thereby creating a new integrated ecosystem encompassing screening, diagnosis, treatment, and management, with precision diagnosis and treatment of chronic cardiovascular and cerebrovascular diseases at its core.